

MODERN SLAVERY STATEMENT 2022

Introduction & background

Mawdsleys Group Investments Limited publishes this statement pursuant to the Modern Slavery Act 2015 ("MSA"), on behalf of itself and its subsidiaries; Mawdsley-Brooks & Company Limited; MBI Pharma Limited; Mawdsleys Pharmaceuticals DO Brasil LTDA; Positive Solutions Limited; and Lowry Pharma Limited (together "Mawdsleys"), to set out the steps taken to combat modern slavery and human trafficking in its businesses.

Mawdsleys is a family-owned business, dating back to 1825 when Thomas Mawdsley launched a wholesale grocery business in Manchester, which evolved into the UK's largest independent pharmaceutical distributor. A true pioneer and champion of rights for working people, Thomas spent many years campaigning for improved working condition in the cotton industry and was one of the parliamentary lobbyists whose efforts resulted in the introduction of The Factories Act 1847 and restrictions on the hours that young people were permitted to work.

Today, people continue to be at the heart of our business. We have built our reputation because of our people, and we remain committed to supporting them and contributing to the prevention and eradication of modern slavery, both within our own workforce and those working for our partners, suppliers and customers. Modern slavery, a crime involving slavery, servitude and forced or compulsory labour, is an abhorrent abuse of human rights and we are fully supportive of the principles of the MSA.

Each financial year Mawdsleys publishes a statement setting out the steps it has taken to tackle modern slavery, pursuant to section 54(1) of the MSA. This is Mawdsleys' fifth statement and relates to the financial year ending 31 March 2022.

Mawdsleys' business and supply chains

Mawdsleys specialises in the provision of products and services to the healthcare and pharmaceutical sector, including purchasing, importing, exporting, warehousing, distributing, supplying and delivering medicinal products and devices, and supplying pharmaceutical over-labelling services, IT solutions and regulatory consultancy services. Given the nature of our businesses, the supply of these products and services continues throughout the year. More information about Mawdsleys and its businesses can be found on the website www.mawdsleys.co.uk.

The board expects the businesses within the Mawdsleys' groups to report on the steps that they have taken to address issues of modern slavery.

Our business practices also aim to prevent violations, such as making on time and sufficient payments and acting fairly in requests and demands for goods and services. Ordering standards of our customers are set to ensure that we are not faced with unmanageable deadlines. Many customers have been



with Mawdsleys for many years, allowing both parties to develop a greater understanding of each other's businesses, to gauge pressure points, manage expectations and minimise risk.

Our supply chains fall mainly into the following categories, in respect of which the risks of modern slavery have been assessed as follows:

- **Suppliers of pharmaceutical products**. The products are sourced globally. The pharmaceutical industry is subject to regulation, approval and licenses which facilitates transparency in the supply chain and assists with the due diligence processes.
- Suppliers of operational goods and services such as IT systems (UK & US based) and transport and logistics services (UK, Brazil and Israel based). Most goods and services are sourced from low-risk territories, but Mawdsleys' undertakes due diligence in the normal course.

We agree codes of conduct with manufacturers, suppliers and clients (including compliance with modern slavery laws), which indicates that this is priority for our partners.

Mawdsleys has dedicated in-house HR and legal departments, complemented by external resources, to ensure compliance with applicable laws and regulations, which employees can access if they have any issues or concerns.

Actions taken in this financial year

During this period the following actions were taken:

- Periodic review of procedures to ensure compliance.
- Updating internal policies.
- Staff training.
- Introduction and enhancement of compliance conditions in commercial contracts.

Actions for the next financial year

We are committed to improving our practices and in the next financial year we will continue with our efforts to educate staff, partners, customers and suppliers on modern slavery and to generally promote good practice in the prevention and eradication of this issue.

William Sanders, Chief Executive Officer